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Rapamycin is a macrolide antibiotic originally isolated from Strepto-
myces hygroscopicus, a bacterium isolated from a soil sample collected
on Easter Island. It was found to suppress the immune system by
blocking T-cell activation and proliferation, and was approved by the
FDA for prophylaxis against organ rejection in renal transplant patients
in 1999. Molecular studies ﬁrst deﬁned a role for rapamycin in complex
with a small isomerase FKBP12 in inhibiting the activity of kinases TOR1
(TOR=Target of Rapamycin) and TOR2 in yeast. Further studies showed
that rapamycin-FKBP12 binds to and inhibits the homologous kinase in
mammalian cells, mTOR. More recently, it has been recognized that
mammalian mTOR forms two large multi-subunit protein complexes,
mTORC1 and mTORC2, that have independent non-overlapping phos-
phorylation targets, and that mTORC1 is the target of rapamycin-
FKBP12 inhibition, while mTORC2 is not (Fig. 1).
The ability of rapamycin to inhibit phosphorylation and activation of
the S6 kinases suggested early on that itmight have cancer growth inhib-
itory properties. Pharmaceutical efforts led to the development of multi-
ple related drugs, collectively termed rapalogs, including everolimus and
temsirolimus. After Phases I–II studies showed promise, randomized
clinical trials demonstrated the beneﬁt of temsirolimus and everolimus
for treatment of patients with metastatic renal cell carcinoma. Everoli-
mus has since also been FDA-approved for neuroendocrine tumors of
pancreatic origin (PNET), breast carcinoma, and subependymal giant
cell astrocytomas (SEGA) associated with tuberous sclerosis.
A major role for the tumor suppressor genes, TSC1 and TSC2, in the
regulation of the S6Ks was ﬁrst identiﬁed in 2002. Subsequent studies
led to a current understanding that the TSC protein complex serves a crit-
ical role in the regulation of mTORC1 activity, through serving as a
GTPase-activating protein (GAP) for RHEB (Fig. 1). Mutations in TSC1
or TSC2 cause the human genetic disease Tuberous Sclerosis Complex
(TSC), and studies in bothmousemodels and human TSC-related tumors
demonstrated that mTORC1 was highly activated in these tumors. After
encouraging initial trials, rapamycin or everolimus have been shown to
have beneﬁt for several TSC tumors or related diseases, including renal
angiomyolipoma, lymphangioleiomyomatosis, and subependymal giant
cell astrocytoma in recent randomized clinical trials (Bissler et al.,
2013; McCormack et al., 2011).
Expanded clinical investigation of rapalogs in various cancers has led
to a recognition that occasional patients display dramatic clinical re-
sponses. The ﬁrst cancer type in which this was seen was PEComa, a
rare sarcoma subtype in which mutations in TSC1 or TSC2 are common.
Several PEComa patients have shown complete response (CR) to
rapalogs lasting over a year including those with massive tumors
(Wagner et al., 2010; Dickson et al., 2013). More recently, Solit and col-
leagues reported a sustained CR in a patient with metastatic bladder
cancer that has now lasted over 4 years (Iyer et al., 2012). TSC1
inactivating mutations have been known in bladder cancer for many
years, and this responding patient had a truncating mutation in TSC1.
This discovery kicked off the current ‘exceptional responder’ initiative
promoted by the NCI. Several other recent reports have identiﬁed pa-
tients with major responses to rapalog therapy, including another pa-
tient with bladder cancer shown to have two activating MTOR
mutations and a patient with anaplastic thyroid cancer shown to have
an inactivating mutation in TSC2 (Wagle et al., 2014a, 2014b). Further-
more a recent report of exceptional responders to rapalogs among pa-
tients with renal cell carcinoma identiﬁed inactivating TSC1 and/or
activatingMTORmutations in 3 of 5 patients (Voss et al., 2014).
In aggregate these studies have identiﬁed inactivating mutations in
TSC1 or TSC2, or activating mutations inMTOR, as correlating with and
presumably accounting for the exquisite sensitivity to rapalogs that
have been seen clinically. Notably, none of PI3K, PTEN, or AKT1/AKT2/
AKT3 mutation has been associated with response to date, likely
reﬂecting their upstream position in this pathway, and their other ef-
fects in addition to mTORC1 activation (Fig. 1). Mutations in other com-
ponents of this pathway, including inactivating mutations in DEPDC5,
NPRL2, and NPRL3, and an activating mutation (Y35N) in RHEB have
been shown to lead to strong mTORC1 activation in vitro, including
analysis of cancer cell lines in some cases (Bar-Peled et al., 2013;
Grabiner et al., 2014).
So can we predict who will respond to rapalog therapy? At present
we cannot. However, we can make some observations and predictions,
and formulate hypotheses for future studies. First, it is clear that there is
a striking correlation between inactivating mutations in TSC1 or TSC2,
and activating mutations inMTOR, and response to rapalog therapy in
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several cancer types. Second, we predict that cancers with activating
mutations in RHEB, or inactivating mutations in DEPDC5, NPRL2, and
NPRL3, will show similar strong response to rapalogs. Third, it is already
clear that not all cancers with mutations in members of this pathway
will show such extraordinary responses (Iyer et al., 2012). Indeed,
there is likely to be a range of responses to rapalogs even for tumors
with activating mutations in the mTOR pathway. There are likely several
explanations for this phenomenon, including as yet unidentiﬁed second-
ary modiﬁer mutations, the tumor cell genetic and epigenetic states, as
well as the possibility that some apparent mutations represent back-
ground noise or are subclonal, and did not contribute substantially to
tumor development. Fourth, it also apparent that not all rapalog re-
sponders have mutations in components of this pathway (Voss et al.,
2014). Apart from the mundane possibility that mutations were missed,
there is the more important possibility that alternative mechanisms con-
tribute to response, including epigenetic silencing events affecting one or
more of the genes encoding proteins that inhibit mTORC1 activation.
Nevertheless, studies of extraordinary responses to rapalogs suggest
that routine screening of cancer patients for alterations in the mTOR
pathway may be helpful to identify a subset of patients who are much
more likely to respond to mTOR-pathway targeted therapies than
other patients. The collective prevalence of mTOR pathway mutations
is appreciable among the common cancers (2.8% on average), including
many cancers inwhich rapalogs are rarely used (e.g. lung adenocarcino-
ma, lung squamous cell carcinoma, melanoma, pancreatic adenocarci-
noma, uterine carcinoma all have a prevalence N1%) — highlighting
the possibility of additional groups of patients who might beneﬁt from
these drugs. These observations have now spawned the so-called “bas-
ket" trials, clinical trials that enroll patients based on speciﬁc mutations
rather than tumor types (e.g. NCT02201212, clinicaltrials.gov). Results
of these trials should help to elucidate the factors that determine exqui-
site dependency on the mTOR pathway as well as the principles of ex-
traordinary responses in general.
One challenge of rapalog basket trials is that the list of cancer genes
and mutations that lead to sensitivity to mTOR inhibitors is incomplete
and still evolving. Ideally, genomically-driven basket trials would have
ﬂexible entry criteria, permitting the range of genes and mutations to
be dynamicallymodiﬁed during the trial, to take advantage of improved
understanding as well as trial experience. In parallel, more detailed
characterization of the functional effects of potential activating muta-
tions inMTOR and RHEB (Grabiner et al., 2014) would be valuable in re-
ﬁning entry criteria for rapalog trials.
There is enormous diversity in the clinical response of patients to
anti-cancer drugs and in most cases we do not understand why. Many
agents in clinical trials “fail” and may be abandoned, yet, as with
rapalogs, there are often a few patients in whom these agents have
profound activity. Studies of exceptional responses demonstrate that
genomic characterization of even a few patients with extraordinary re-
sponses can yield important insights. These studies could help us devel-
op methods for matching patients to drugs, highlight effective uses for
otherwise “failed” therapies, and design new therapeutic strategies.
Findings from these studies may also help us understand mechanisms
of therapeutic resistance when it emerges, and may help develop strat-
egies to overcome such resistance (Wagle et al., 2014a). Unlike other
large-scale cancer genomics efforts, identifying and characterizing the
tumors from even a few extraordinary responses can lead to major in-
sight and advances in cancer therapy.
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Fig. 1. Regulation ofmTORC1. The TSC complex, comprised of TSC1, TSC2, and TBC1D7 plays a critical role in regulating RHEB-GTP levels and therebymTORC1 activity. The TSC complex is
negatively regulated by phosphorylation by AKT, ERK, and RSK, all core kinases activated during growth signaling, downstream of receptor tyrosine kinases (RTKs) and phosphatidyl ino-
sitol 3-kinase (PI3K). PTEN turns off PI3K-derived signaling events by reducing PI3P levels. mTORC1 is also regulated by the rag GTPases which are inactivated by the GATOR1 complex,
made up of DEPDC5, NPRL2, and NPRL3. mTORC1 stimulates cell size increase and growth through several anabolic effects (not shown). Inactivating mutations in any of TSC1, TSC2,
DEPDC5, NPRL2, or NPRL3 can lead to mTORC1 activation. Activating mutations in either RHEB or MTOR can lead to mTORC1 activation. The mTOR protein occurs in either of two large
protein complexes, mTORC1 and mTORC2. Arrows indicate stimulatory events, which at times are mediated by phosphorylation (+P); blocked lines indicate inhibitory effects.
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